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The objective of present work was to utilize potential of nanostructured lipid carriers (NLCs)
for improvement in oral bioavailability of raloxifene hydrochloride (RLX). RLX loaded NLCs
were prepared by solvent diffusion method using glyceryl monostearate and Capmul MCM C8
as solid lipid and liquid lipid, respectively. A full 32 factorial design was utilized to study the
effect of two independent parameters namely solid lipid to liquid lipid ratio and concentration
of stabilizer on the entrapment efﬁciency of prepared NLCs. The statistical evaluation
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Amorphous natureconﬁrmed pronounced improvement in entrapment efﬁciency when liquid lipid content in the
formulation increased from 5% w/w to 15% w/w. Solid-state characterization studies (DSC
and XRD) in optimized formulation NLC-8 revealed transformation of RLX from crystalline
to amorphous form. Optimized formulation showed 32.50 ± 5.12 nm average particle size and
12.8 ± 3.2 mV zeta potential that impart good stability of NLCs dispersion. In vitro release
study showed burst release for initial 8 h followed by sustained release up to 36 h. TEM study
conﬁrmed smooth surface discrete spherical nano sized particles. To draw ﬁnal conclusion,
in vivo pharmacokinetic study was carried out that showed 3.75-fold enhancements in bioavail-
ability with optimized NLCs formulation than plain drug suspension. These results showed
potential of NLCs for signiﬁcant improvement in oral bioavailability of poorly soluble RLX.
 2016 Production and hosting by Elsevier B.V. on behalf of Cairo University.Introduction
The oral route is the most imperative route for administering
varieties of drugs. It has been extensively used for both con-
ventional and novel drug delivery systems. In spite of the wide
success with some other routes for drug administration, the
oral route is still most preferred route for its vast qualities.
Raloxifene hydrochloride (RLX) is a selective estrogen
receptor modulator (SERM) with a proven estrogen agonist
action on bone that leads to an improvement in bone mass
[1] and a reduction in vertebral fractures [2]. RLX is poorly
soluble drug as it belongs to class II category according to
BCS classiﬁcation. RLX has oral bioavailability of only 2%
owing to extensive ﬁrst pass metabolism. Therefore, it is neces-
sary to increase the solubility and dissolution rate of RLX
which lead to improvement in oral bioavailability [3].
Enhancement in oral bioavailability can be achieved by
reducing the hepatic ﬁrst pass metabolism. Such problem with
conventional dosage form can be minimized by any suitable
novel drug delivery system such as prodrug concept or by
the use of novel lipid based system such as lipid nanoparticles,
microemulsion [4] and Self emulsifying microemulsion drug
delivery system [5].
Since last decade, various techniques have been studied to
formulate nanoparticulate carrier systems [6]. Polymeric and
solid lipid nanoparticles (SLNs) are two varieties of such nano
carrier systems. Polymeric nanoparticles suffered with some
drawbacks such as toxicity and unavailability of some good
techniques for production of nanoparticles at large scale. Com-
pared to polymeric nanoparticles, SLNs gain some advantages
in terms of less toxicological risk because of natural origin
lipids. Despite SLNs being good carriers, less capacity of drug
loading and expulsion of the drug during storage may require
to think of some good technique to overcome such problems.
As an effect, nanostructured lipid carriers (NLCs) have been
developed, which in some extent can avoid the aforementioned
limitations. NLCs can be deﬁned as a second generation of
SLNs having solid lipid and liquid lipid (oil) matrix that create
a less ordered or imperfect structure which helps in improving
drug loading and decreasing the drug expulsion from the
matrix during storage period [7,8]. In the present work, RLX
loaded NLCs were developed by solvent diffusion method as
this method has remarkable advantages such as use of simple
equipment accessories, easiness in handling and quick manu-
facturing [9].
The aim of present research work was to develop stable
RLX loaded NLCs formulation using solvent diffusionmethod and to evaluate in vitro characteristics and in vivo
pharmacokinetic parameters of prepared formulation.
Material and methods
Materials
RLX was gifted from Aarti drugs Pvt Ltd, Mumbai, India.
Dynasan 114 (Trimyristin) and Dynasan 118 (Tristearin) were
gifted from Cremer Oleo GmbH & Co. KG, Germany. Glyc-
eryl monostearate (GMS), Isopropyl myristate, oleic acid,
polyvinyl alcohol (PVA) and stearic acid were purchased from
Loba Chemie, Mumbai, India. Capmul MCM C8, Labraﬁl
ICM 1944 CS and Labrafec CC were gifted from Abitec Cor-
poration, Janesville, USA. All other reagents used in research
work were of analytical grade.
Methods
Selection of solid lipid
Solid lipid was selected by checking the solubility of the drug
in melted solid lipid by means of visible observation with the
naked eyes under normal light [10–13]. Lipids used for this
study were Dynasan 114, Dynasan 118, stearic acid and
GMS. Weighed quantity of drug (50 mg) separately with var-
ious lipids (5 g each) was heated above the melting point of
lipid in a temperature regulated water bath (Macro Scientiﬁc
Work Pvt Ltd, Delhi, India) in 10 mL glass vials. After melting
of lipid, the solubility of RLX in each lipid was observed visu-
ally under normal light [14,15].
Partition behavior of RLX in various solid lipids
Weighed quantity of drug (25 mg) was added into the blend of
melted solid lipid (5 g) and hot water (5 g). Mixture was sha-
ken on an isothermal orbital shaker (MSW-132, Macro Scien-
tiﬁc Work Pvt Ltd, Delhi, India) at 70 ± 2.0 C for 24 h to
reach equilibrium followed by separation of aqueous phase
through centrifugation at 5000 rpm for 5 min using cooling
centrifuge (C-24 BL, Remi Instrument Pvt Ltd, Mumbai,
India). Drug content was analyzed spectroscopically at
288 nm using UV visible spectrophotometer (UV-1800, Shi-
madzu, Japan) [13,16].
Selection of liquid lipid
Liquid lipid was selected based on the maximum solubility of
the drug in different liquid lipids. Lipids used for this study
Table 2 The central composite experimental design for RLX
loaded NLCs.
Formulation code X1 X2
NLC-1 1 1
NLC-2 1 0
NLC-3 1 1
NLC-4 0 1
NLC-5 0 0
NLC-6 0 1
NLC-7 1 1
NLC-8 1 0
NLC-9 1 1
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raﬁl ILM 1944 CS and Lebrafec CC. Excess amount of drug
was taken in stopper vials containing 5 g of liquid lipids and
mixing was carried out on a vortex mixer for 10 min. There-
after, vials were kept in an isothermal orbital shaker at 25
± 2.0 C for 24 h to reach equilibrium. Supernatant was sepa-
rated by centrifugation at 5000 rpm for 15 min and analyzed
spectroscopically at 289 nm [17–19].
Formulation of RLX loaded NLCs
Design of the experiment
A complete 32 factorial design was utilized to study the
effect of two independent variables namely solid lipid to
liquid lipid concentration and stabilizer concentration on
entrapment efﬁciency of drug in prepared formulations.
Variables and levels used for optimization of RLX loaded
NLCs are shown in Table 1. Based on preformulation stud-
ies discussed earlier GMS, Capmul MCM C8 and PVA
were selected as solid lipid, liquid lipid and stabilizer,
respectively.
Preparation of NLCs
NLCs loaded with RLX were developed using solvent diffu-
sion method in aqueous system with some modiﬁcation [20].
Drug (5% w/w to the total weight of drug and lipids) and
Capmul MCM C8 were mixed in a 10 mL solvent mixture
of ethanol and acetone (1:1 v/v) followed by bath sonication
(SW-4, Toshniwal Instruments Pvt Ltd, Ajmer, India) for
10 min [13]. The obtained mixture was kept on a water bath
maintained at 60 C followed by addition of GMS to make
clear solution of lipids and drug in organic solvent system.
The resultant organic mixture was hastily added into
100 mL of an aqueous phase comprising of PVA as stabilizer
kept on water bath maintained at 70 C under mechanical
agitation of 500 rpm for 10 min using mechanical stirrer
(RQ-121/D, Remi Instrument Pvt Ltd, Mumbai, India).
The obtained RLX loaded NLCs dispersion was cooled at
room temperature for 20 min on magnetic stirrer for the
liberation of organic solvent [20–23]. The prepared NLCs
dispersion was transferred to centrifuge tubes equipped with
cooling centrifuge and centrifugation was carried out for
17,000 rpm and 1 h at 10 C [11,13,21] to separate precipi-
tated NLCs. NLCs were collected and lyophilized using
freeze dryer (MSW-137, Macro Scientiﬁc Work Pvt Ltd,
Delhi, India). Composition of prepared NLCs formulations
is shown in Table 2.Table 1 Variables and levels used in 32 factorial design for
RLX loaded NLCs.
Factors Levels
1 0 1
X1 95:5 90:10 85:15
X2 0.5 1.0 1.5
X1 = Solid:liquid lipid ratio (% w/w), X2 = Concentration of
stabilizer (% w/v).Evaluation of RLX loaded NLCs
Percentage yield
The percentage yield was determined by dividing the weight of
recovered nanoparticles with the weight of drug and lipids
used for the preparation of nanoparticles.
Percentage Yield ¼Weight of recovered nanoparticles
Theoretical weightðdrugþ lipidsÞ  100Drug loading and entrapment efficiency
The prepared NLCs dispersion was centrifuged by aforemen-
tioned experimental parameters. Supernatant was separated,
diluted and determined for RLX content spectroscopically at
288 nm.
Entrapment efﬁciency of drug was calculated as follows
[11,24]:
% Entrapment efficiency ¼ ½RLXtotal  ½RLXsupernatant½RLXtotal
 100
where ‘‘[RLX]total” is the weight of total incorporated drug
and the ‘‘RLXsupernatant” is the weight of free drug analyzed
in supernatant layer.
Loading capacity of drug was calculated as follows [11,25]:
%Drug loading¼Amount of RLX entrapped in NLCs
Amount of RLX and lipids added
100Optimization of formulation
The optimization of prepared formulations was done by con-
sidering percentage drug entrapment and studying interaction
between factors as discussed underneath.
Interaction between the factors
The statistical evaluation of all the obtained results data was
carried out by analysis of variance (ANOVA) using Microsoft
excel version 2007. The ANOVA results (P value) showed the
effect of various independent variables on dependent parame-
ter such as percentage drug entrapment. After regression anal-
ysis of all formulations, full polynomial model was obtained
followed by omission of non-signiﬁcant terms (P> 0.05) to
obtain reduced model for the analysis. This equation repre-
sents effect of independent formulation variables on entrap-
ment efﬁciency.
426 N.V. Shah et al.Construction of contour and response surface plots
Both plots were constructed from reduced polynomial equa-
tion using sigma plot version 11.0 by keeping one parameter
stationary and varying others.
Evaluation of model/check point analysis
Checkpoint analysis was carried out to evaluate the depend-
ability of the model through comparison between experimental
and predicted values of the responses.
In vitro drug release studies
In vitro drug release of plain drug suspension and prepared
NLCs was carried out using the dialysis sac method [10]
(Himedia-Dialysis membrane 135, Mol. cut off 12,000–
14,000 Da, Mumbai, India). An accurately measured amount
of plain drug suspension and NLCs formulations equivalent
to 5 mg of RLX were introduced into sac and both ends of
the sac were tied with the help of thread. The sac was hanged
with the assistance of thread in beaker comprising of 200 mL
of Citro phosphate buffer pH 7.6 with 1% of polysorbate 80
kept on magnetic stirrer [10,26,27]. The temperature of the
receptor compartment was maintained at 37 ± 1 C. Aliquots
of 5 mL were withdrawn at predeﬁned time interval with a pip-
ette and replaced with fresh buffer at each time. The ﬁltered
samples (0.45 lm membrane ﬁlter) were analyzed spectroscop-
ically at 288 nm. Blank formulations were prepared and trea-
ted in same manner as discussed above. Blank formulations
were taken for base correction by suitable dilution with buffer
system in UV–Visible spectrophotometer to nullify any effect
of ingredients used in formulation other than drug. Each test
was carried out in triplicate.
Characterization of optimized RLX loaded NLCs
Fourier transform infrared (FTIR) spectroscopy
FTIR spectra were recorded by FTIR spectrometer
(IRAfﬁnity-1, Shimadzu, Japan) to study any interaction
between drug and excipients. Samples were mixed with KBr
in a ratio of 1:300 and spectrum was recorded in the range
of 4000–400 cm1.
Characterization of particle size and zeta potential
The particle size and zeta potential of optimize formulation
NLC-8 were measured by Malvern zeta sizer (Nano ZS, Mal-
vern Instruments, Worcestershire, UK) after suitable dilution
with distilled water.
Differential scanning calorimetry (DSC) analysis
Thermogram of samples was recorded by Differential scanning
calorimeter (DSC TA – 60, Shimadzu, Japan). Samples were
weighed directly in aluminum pan and scanned at 50–300 C
temperature under dry nitrogen atmosphere at the heating rate
of 10 C/min.
X-ray diffraction (XRD) study
XRD study of samples was performed by Panalytical Xpert
PRO X-ray Diffractometer (Xpert Pro MPD, Panalytical,Netherlands) where CuKa radiation wavelength of 1.5405 A˚
was used as X-ray source. For the measurements, samples were
kept in the glass sample holders followed by scanning from 2
to 60 with scan angular speed (2h/min) of 2/min, 40 kV
working voltage and 30 mA current.
Surface morphology study
Surface morphology of optimized formulation NLC-8 was
studied by Transmission Electron Microscope (TEM) (Philips
Tecnai – 20, USA). NLCs were dispersed in distilled water and
a drop of dispersion was placed on carbon coated copper grid
followed by drying. This grid was mounted in the instrument
and photographs were taken at various magniﬁcations.
Stability study
Freeze-dried optimized formulation was subjected to stability
studies as per ICH guidelines. The samples were placed in vials
and kept at 25 ± 2 C/60 ± 5% RH and 40 ± 2 C/75 ± 5%
RH atmospheric conditions using stability chamber (Macro
scientiﬁc work Pvt Ltd, Delhi, India) over period of six
months. The samples were analyzed for entrapment efﬁciency
and physical appearance at speciﬁed time intervals (0, 15, 30,
60, 120 and 180 days of storage). Cumulative drug release
study was also carried out at the end of stability study for both
storage conditions.
In vivo pharmacokinetic study
To study the bioavailability of RLX, in vivo pharmacokinetic
study was carried out for optimized formulation (NLC-8)
and plain drug suspension as per the below discussed protocol.
Experimental animals
The experimental protocol in the present study was approved by
the Committee for the Purpose of Control and Supervision of
Experiments on Animals (CPCSEA) and the Institutional Ani-
mal Ethics Committee (IAEC) of SBKS medical college and
research institute, Sumandeep Vidyapeeth, Vadodara, India with
clearance No. SVU/DP/IAEC/2014/03/18. The experiment was
carried out on healthy female Wistar rats with weight range
from 200 to 250 g [10]. Rats were kept in polypropylene cages,
under standard situation (12 h light/dark cycle, 24 C, 35–60%
humidity) with free access to diet (Nav Maharashtra oil mills
ltd, Pune, India) and drinking water ad libitum [28,29].
Bioanalytical method
In the present work, chromatographic separation was carried
out by previously validated chromatographic method [28]
using HPLC (UFLC, Shimadzu Corporation, Japan) promi-
nence liquid chromatographic system which is controlled by
LC solution software (Version 1.24 Sp1, Shimadzu Corpora-
tion, Japan). The system was equipped with Binary pump
(LC 20AD version 1.10, Shimadzu corporation, Japan), a
manual injector, a column (C18 250 mm  4.6 mm, 5 lm)
(Luna, Phenominax, USA) and a photo diode array (PDA)
detector (SPD 20A version 1.08, Shimadzu corporation,
Japan). Freshly prepared, sonicated and ﬁltered (0.45 lm
membrane ﬁlter) mobile phase consisted of a 67% 0.05 M
ammonium acetate buffer (pH was adjusted to 4.0 with glacial
Table 4 Partition coefﬁcient of RLX in various solid lipids.
Sr. no. Name of lipid system Apparent partition coeﬃcient ± SD
1 Water/Dynasan 114 59.58 ± 3.69
2 Water/Dynasan 118 72.89 ± 10.47
3 Water/Stearic acid 66.34 ± 5.41
4 Water/GMS 85.12 ± 9.48
Value are expressed as mean ± SD, n= 3.
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1 mL min1 to elute the drug [26,28,30]. The samples were
injected at 20 lL volume and analyzed at 288 nm.
Preparation of standard solution
A series of standard solutions of RLX ranging from 20 to
1000 ng/mL were prepared in methanol. Samples were pre-
pared by addition of 50 lL of standard solution and 200 lL
of acetonitrile to the eppendorf tube containing 100 lL of
blank plasma. The mixture was then processed according to
the sample treatment procedure described below [28]. Final
RLX concentrations in plasma were 10–500 ng/mL.
Sample treatment procedure
The eppendorf tube consisting of an aforementioned mixture
was meticulously vortex-mixed (Macro Scientiﬁc Work Pvt
Ltd, Delhi, India) for 30 s followed by centrifugation at
15,000 rpm for 10 min at 6 C to separate denatured protein.
After centrifugation, 20 lL of the ﬁltered supernatant (0.45 lm
membrane ﬁlter) was injected into HPLC system and analyzed
at 288 nm [28,30].
Experimental design
Before dosing, the animals were fasted for the period of 12 h
prior and 4 h post with free access to water. Animals were
divided into two groups consisting of six animals in each. Con-
trol group received an suspension of RLX (drug suspended in
0.5% w/v sodium CMC [10,12]) and the test group received the
optimized formulation (NLC-8) at a dose of 15 mg/kg body
weight, p.o [26,28].
Serial blood samples (0.5 mL) were withdrawn through
capillary inserted into retro-orbital plexus under mild ether
anesthesia at a time interval of predose, 0.25, 1, 2, 4, 6, 8,
10, 12, 16, 20 and 24 h post dose as described in Table 3.
The samples were transferred into micro centrifuge tubes con-
taining anticoagulant (3.8% w/v sodium citrate [26]). The
plasma samples were collected immediately from aforemen-
tioned samples by centrifugation at 5,000 rpm for 10 min at
4 C and stored in micro centrifuge tubes at 20 C until anal-Table 3 The collection of blood samples from each rat of one grou
Number of rats (n= 6) in each group
Pre-dose 0.25 1
Group – I (Control group)
1 U U
2 U
3 U U
4 U
5 U U
6 U
Group – II (Optimized formulation)
1 U U
2 U
3 U U
4 U
5 U U
6 U
‘U’ indicates the 0.5 mL blood sample withdrawn from alternate eyes of
Total blood volume collected from each animal is 3.0 mL.ysis [10,31]. Samples were analyzed by standard HPLC method
after sample treatment procedure as discussed earlier.
Pharmacokinetic data analysis
PK solver add-in program for Microsoft excel (version 1.0,
China) was used for the estimation of Pharmacokinetic param-
eters. The maximum plasma concentration (Cmax) and the time
to reach maximum plasma concentration (Tmax) were obtained
directly from the graph between plasma concentration and
time. Area under curve [AUC]0–24 was considered up to last
point of measurement. Relative bioavailability (F) was calcu-
lated by dividing [AUC]0–24 of formulation with plain drug
suspension [12]. Each experiment was carried out in triplicate.
Statistical analysis
The obtained data were statistical analyzed by one way analy-
sis of variance (ANOVA) using student’s t-test. Graph Pad
Instat program version 3.01 (Graph Pad Software, Inc. CA,
USA) was utilized to determine the signiﬁcance difference
between formulations. The level of statistically signiﬁcance
was selected as P< 0.05.
Results and discussion
Selection of solid lipid
A selection of suitable lipids and other excipients is signiﬁcant
to develop NLCs for poorly soluble RLX. To keep the drug in
solubilization form, it is of prime importance that drug hasp at different time intervals.
Time of collection (h)
2 4 6 8 10 12 16 20 24
U U U U
U U U U U
U U U U
U U U U U
U U U U
U U U U U
U U U U
U U U U U
U U U U
U U U U U
U U U U
U U U U U
each animal.
428 N.V. Shah et al.higher solubility in solid lipid. It was found from the study that
drug solubility in Dynasan 114, Dynasan 118 and stearic acid
was indistinct but found fairly visible in GMS.
Partition behavior of RLX in various solid lipids
Determination of partition behavior of drug in lipid is impor-
tant criterion in controlling two parameters namely drug
entrapment efﬁciency and drug release proﬁle. Therefore, the
success of development of NLCs is depending on selection of
proper lipid for formulation of nanoparticles. From the result
shown in Table 4, it was found that RLX had higher partition-
ing in GMS compared to other lipids. This ﬁnding also sup-
ported the high solubility of drug in GMS as discussed
earlier. Therefore, GMS was chosen as solid lipid for develop-
ment of NLCs owing to its high potential for solubilization
and thereby entrapment of more amount of drug in NLCs
formulation.
Selection of liquid lipid
As discussed earlier for solid lipid, a variety of short chain liq-
uid lipids is also playing major role in entrapment of more
amount of drug in case of NLCs formulation. It was found
from the result that Capmul MCM C8 has maximum drug sol-Fig. 1 (A) Graphical comparison of % yield between different
concentrations of stabilizer (*P< 0.05) [result of three columns
represents average % yield of batches (NLC-1, NLC-4 and NLC-
7), (NLC-2, NLC-5 and NLC-8) and (NLC-3, NLC-6 and NLC-
9), respectively] and (B) graphical comparison of % entrapment
efﬁciency with different solid lipid:liquid lipid ratios (*P< 0.05)
[result of three columns represents average % entrapment
efﬁciency of batches NLC 1–3, NLC 4–5 and NLC 7–9,
respectively].ubility (2.55 ± 0.96 mg/g) than Isopropyl myristate (1.14
± 0.14 mg/g), Oleic acid (2.08 ± 0.24 mg/g), Labraﬁl IC M
1944 CS (1.24 ± 0.18 mg/g) and Lebrafec CC (0.74
± 0.07 mg/g). Therefore, Capmul MCM C8 was selected as
liquid lipid to make a matrix with solid lipid GMS for the
development of NLCs.
Evaluation of RLX loaded NLCs
Percentage yield, drug loading and entrapment efficiency
The Percentage yield of NLCs formulations was found with
signiﬁcant differences ranging from 80.15 ± 3.54 to 93.85
± 2.17%. The observed difference may be because of stabilizer
concentration. It was noted from Fig. 1A that percentage yield
of NLCs was increasing signiﬁcantly with stabilizer concentra-
tion increased from 0.5% to 1.0% w/v (P< 0.05) but non-
signiﬁcant increment observed with concentration from 1.0%
to 1.5% w/v. Hence, it can be conclude that formulation with
optimum 1.0% w/v PVA concentration may achieve maximum
nanoparticles yield with good stability.
The drug entrapment efﬁciency and loading capability of
NLCs were remarkably increased from 30.83 ± 2.39 to
74.78 ± 3.34% and from 1.92 ± 0.12 to 4.02 ± 0.17%,
respectively with increasing the proportion of Capmul MCM
C8 from 5 to 15% w/w. Furthermore, it was reported that
Capmul MCM C8 being a Mono glycerides of caprylic acid
form unstructured matrix with many imperfections providing
a space to incorporate more amount of drug [32–35]. As shown
in Fig. 1B, it was observed that 15% w/w liquid lipid content
in formulation improves drug entrapment signiﬁcantly
(P< 0.05) compared to 5% w/w and 10% w/w liquid lipid
content. High proportion of liquid lipid may help in increasing
drug solubility in lipid matrix followed by high entrapment
efﬁciency.
Optimization of formulation
Interaction between the factors
A 32 full factorial design was employed in optimizing the for-
mula. The concentration of GMS: Capmul MCM C8 (X1) and
concentration of PVA solution (X2) were taken as the indepen-
dent variables and the entrapment efﬁciency as the dependent
variable. The maximum percent entrapment (74.78%) was
found at 1 level of X1 and 0 level of X2 as shown in Fig. 2A.
The entrapment efﬁciency was obtained by conducting system-
atic experiments at various levels and was subjected to regres-
sion analysis to obtain a polynomial equation of the full model
as follows:
Y ¼ 58:39þ 17:07X1 þ 5:21X2  1:11X21  6:52X22 þ 0:56X1X2
Non-signiﬁcant terms were rejected (P> 0.05) to obtain
reduced model as follows:
Y ¼ 58:39þ 17:07X1 þ 5:21X2  6:52X22
Based on the P value, X1, X2 and X2
2 factors were found to
be signiﬁcant and all other factors were found to be insigniﬁ-
cant. For the given model, calculated F value was found very
low than the tabular F value (/= 0.05, 2) so it can be con-
ﬁrmed that the omitted terms do not signiﬁcantly contribute
Fig. 2 (A) Contour plot and (B) 3D surface response plot for levels of solid lipid:liquid lipid and concentration of stabilizer with %
entrapment of prepared NLCs.
Fig. 3 Comparison of in vitro drug release proﬁle between NLCs and plain drug suspension.
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value of X1 reveals that it can affect the maximum entrapment
efﬁciency. However, at the same time the value of X2
2 was also
found to be signiﬁcant. Therefore, the concentration of surfac-
tant can also be considered as critical factor in formulation
along with concentration of solid lipid to liquid lipid.
Contour/response surface plots
Contour and response surface plot were drawn at the selected
values of the independent variables. The plots shown in
Fig. 2B were found to be nonlinear and having curved segmentfor each preﬁxed values that signify nonlinear relationship
between the selected variables.
Check point analysis
Check point analysis was performed to verify the effectiveness
of established contour plot and reduced polynomial equation
in development of drug loaded NLCs. The percent error for
entrapment efﬁciency in the check point analysis was found
to be very less between theoretical value and experimental
value. This ﬁnding signiﬁes the role of the reduced model, con-
tour plots and the check point analysis in the mathematical
430 N.V. Shah et al.modeling. By studying full 32 factorial design, it was notiﬁed
that formulation NLC-8 showing maximum entrapment efﬁ-
ciency of 74.78 ± 3.34% and may be optimized for
further characterization but that can be conﬁrmed only after
performing in vitro release study of all prepared NLCs
formulations.
In vitro drug release
In vitro release proﬁle of RLX from all NLCs formulations
portrayed in Fig. 3 showed burst drug release for initial 8 h fol-
lowed by slow and sustained release up to 36 h. However from
the data, it was found that drug release proﬁle of RLX was
improving from formulations NLC-1 to NLC-9 as the concen-
tration of liquid lipid in formulations increases. The formula-
tion containing 15% w/w Capmul MCM (NLC-8) showed
considerable improvement in release proﬁle (90.82 ± 2.4%)
compared to other NLCs formulations. Therefore, NLC-8Fig. 4 Fourier transform infrared spectra of (A) RLX, (B) physical m
C8 and RLX, (D) physical mixture of RLX, GMS and Capmul MCMformulation was selected for further characterization based
on its improved drug release proﬁle and maximum drug
entrapment efﬁciency optimized by 32 factorial design. The
optimized formulation (NLC-8) also showed signiﬁcant
enhancement (P< 0.05) in drug release proﬁle compared with
plain drug suspension as shown in Fig. 3.
Such type of drug release pattern in NLCs was most likely
related to allotment of liquid lipid in nanoparticles. It was
reported in earlier study [20] that when NLCs were prepared
by solvent diffusion method at 70 C, liquid lipid was not allot-
ted equivalently with solid lipid matrix. In such cases, more
amounts of liquid lipid remain at the external shell of nanopar-
ticles and very less liquid lipid incorporated into the center
during cool process [22]. Therefore, the external part of parti-
cles becomes soft and exhibited signiﬁcantly more solubility
for hydrophobic drugs which imparts initial burst effect in
release proﬁle [36].ixture of GMS and RLX, (C) physical mixture of Capmul MCM
C8 (E) optimized batch NLC-8.
Fig. 6 X-ray diffraction patterns of (A) RLX, (B) GMS, (C)
physical mixture of RLX, GMS and Capmul MCM C8 (D)
optimized batch NLC-8.
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release pattern of optimized formulation. The release kinetics
of optimized formulation calculated by the regression analysis
(R2 value) had higher linearity for zero order and Higuchi
model. Therefore, it can be concluded that optimized formula-
tion NLC-8 follows zero order kinetics with diffusion con-
trolled release mechanism as per Higuchi model.
Characterization of optimized RLX loaded NLCs
FTIR spectroscopy
As shown in Fig. 4E of NLC-8, it was observed that character-
istic peaks of drug 947.00 cm1 (Benzene ring), 1458.18 cm1
(–S– benzothiophene) and 1600.92 cm1 (–C–O–C– stretching)
were found to be similar with pure drug spectra as shown in
Fig. 4A. This reveals no physicochemical interaction between
drug and excipients in NLCs formulation.
Particle size and zeta potential
The particle size of NLC-8 showed considerably smaller mean
size of 32.50 ± 5.12 nm with less polydispersive index that rep-
resents narrow distribution of nanoparticles within the system.
Zeta potential is necessary for analyzing stability of colloidal
dispersion during storage. The zeta potential of optimized for-
mulation was found to be 12.8 ± 3.2 mV, which imparts
good stability of NLCs dispersion.
Differential scanning calorimetry
Thermogram of RLX and GMS showed endothermic peaks at
272.92 C and 62.89 C corresponding to their melting points
as depicted in Fig. 5A and B, respectively. DSC plot of physi-
cal mixture shown in Fig. 5C showed sharp peaks at 272.18 C
and 61.94 C representing melting points of drug and GMS,
respectively. Thermogram of NLC-8 (Fig. 5D) showed
endothermic peak at 63.42 C representing the melting point
of GMS but the absence of endothermic peak within the melt-
ing range of RLX indicates either solubilization or conversionFig. 5 Differential scanning calorimetry thermograms of (A)
RLX, (B) GMS, (C) physical mixture of RLX, GMS and Capmul
MCM C8 (D) optimized batch NLC-8.of drug from crystalline to amorphous form in the solid and
liquid matrix.
X-ray diffraction study
The XRD study was carried out with support of DSC to verify
the reduction in crystalline nature of RLX in prepared formu-
lation. The XRD spectrums of drug in Fig. 6A and physical
mixture in Fig. 6C showed distinct and intense peaks at 2h
scale indicate crystalline nature of drug. In contrast, there
was a considerable decline in intensity of all peaks in XRD
pattern of NLC-8 as shown in Fig. 6D. Therefore, it can be
revealed that RLX drug is completely in amorphous state in
optimized NLCs formulation with solid lipid and liquid lipid.
Surface morphology study
TEM study showed the discrete NLCs particles with spherical
shape and smooth surface as shown in Fig. 7. The spherical
shape of NLCs has been reported in previous ﬁndings
[22,37]. In addition, TEM image also conﬁrms nano sizeFig. 7 Transmission electron microscopy image of optimized
batch NLC-8. The magniﬁcations are 65,000.
Table 5 Stability study data for optimized formulation (NLC-8).
Sr. no. Time (days) 25 C± 2 C/60%± 5% RH 40 C± 2 C/75%± 5% RH
Physical appearance Entrapment eﬃciency ± SD (%) Physical appearance Entrapment eﬃciency
± SD (%)
1 0 Yellow free ﬂowing Powder 74.78 ± 3.34 Yellow free ﬂowing Powder 74.78 ± 3.34
2 15 74.71 ± 3.18 74.44 ± 2.25
3 30 74.63 ± 2.10 74.07 ± 2.44
4 60 73.88 ± 3.52 73.11 ± 0.85
5 120 73.92 ± 2.47 71.81 ± 1.64
6 180 73.85 ± 1.18* 70.05 ± 1.26**
Value are expressed as mean ± SD; n= 3.
* P> 0.05.
** P< 0.05.
Fig. 8 Plasma concentration versus time proﬁle of the optimized
NLC-8 and plain drug suspension following oral administration to
Wistar rats.
432 N.V. Shah et al.(<50 nm) of prepared NLCs that support the result obtained
with particle size measurement by zetasizer.
Stability study
The result of stability study is depicted in Table 5. At the end
of study, no change was observed in physical appearance of
formulation in both stability conditions but signiﬁcant reduc-
tion was notiﬁed in entrapment efﬁciency at accelerated condi-
tion. The release rate for the formulation kept at room
condition was satisfactory but showed signiﬁcant reduction
(P< 0.05, data not shown) at accelerated conditions. The
result shown for accelerated condition may attribute small
degradation of drug at this condition which supports the fact
that accelerated temperature is not a suitable storage conditionTable 6 Comparative study of the pharmacokinetic parameters of
Sample P
Cmax ± SD (ng/mL) Tmax (h)
Plain RLX suspension 37.88 ± 3.99 8
NLC-8 207.63 ± 15.81* 4
Value are expressed as mean ± SD; n= 3, F – Relative bioavailability.
* P< 0.05 compared with plain RLX suspension.for lipid based formulation. Therefore, it can be concluded
that the room condition (25 ± 2 C/60 ± 5% RH) is a more
favorable storage condition than the accelerated condition
for NLCs formulation for a longer period of time.
In vivo pharmacokinetic study
RLX was found to be well separated under used HPLC condi-
tions. Retention time of drug was found to be 5.346
± 0.21 min. Standard curve of RLX for estimation in rat
blood plasma showed linearity in the concentration range of
10–500 ng/mL with equation Y= 21.22 X+ 904.5 and regres-
sion coefﬁcient of 0.982 at kmax 288 nm.
The oral bioavailability of RLX is very much limited due to
its poor water solubility and extensive ﬁrst pass metabolism.
Therefore, an attempt was made to improve bioavailability
of RLX using the concept of novel drug delivery system. In
the present work, plain drug suspension and optimized NLCs
were administered orally to female Wistar rats for estimation
of various pharmacokinetic parameters.
Fig. 8 illustrates the higher Cmax for NLC-8 formulation
(207.63 ± 15.81 ng/mL) with respect to plain drug suspension
(37.88 ± 3.99 ng/mL). The [AUC]0–24 that denote the extent of
absorption was found 3.75-fold signiﬁcantly higher (P< 0.05)
in NLC-8 formulation (1817.72 ± 81.42 ng h/mL) compared
to plain drug suspension (484.83 ± 32.16 ng h/mL) as shown
in Table 6. This signiﬁcance increase in [AUC]0–24 for NLCs
may be due to its nano size and the avoidance of ﬁrst pass
metabolism through lymphatic transport pathway.
Many attempts have been made to improve the oral
bioavailability of poorly soluble RLX by using conventional
carriers such as solid dispersion and inclusion complex or by
utilizing the potential of SLNs. However drug encapsulated
in NLCs has proven more superior over the others as far as
the oral bioavailability is concerned. In case of SLNs, they
suffered with some issues of low drug loading capacity andoptimized batch NLC-8 and plain drug suspension.
harmacokinetic parameters
[AUC]0–24 ± SD (ng h/mL) t1/2 (h) ± SD F
484.83 ± 32.16 16.01 ± 1.91 –
1817.72 ± 81.42* 9.93 ± 2.12 3.75
Nanocarriers for bioavailability enhancement of poorly soluble raloxifene 433potential expulsion of drug due to crystallization of pure solid
lipid into perfect lattice during manufacturing process and due
to time dependant restructuring process of lipid molecules dur-
ing storage period, respectively that might ultimately lower the
performance of SLNs in terms of bioavailability [38]. Such
issues can be conquered by the formulation of NLCs due to
its unstructured imperfect matrix formed between solid and
liquid lipid and this may lead to improvement in drug loading
with reduction in expulsion of drug during storage condition
which eventually played a role in enhancement of bioavailabil-
ity of drug. In case of conventional techniques, they suffered
with problem of hepatic metabolism of drug at some extent
which can be avoided by large margin through the encapsula-
tion of drug in nano carriers such as NLCs. NLCs can trans-
port the drug by lymphatic delivery through thoracic lymph
ducts to the systemic circulation [39,40]. Some other mecha-
nism such as reduction in efﬂux of drug from intestinal mem-
brane due to modulation of p-glycoprotein inhibitory function
might be also responsible for enhancement of bioavailability of
RLX by formulating NLCs.
Conclusion
In the present study, an attempt was made to improve
bioavailability of poorly soluble RLX by preparing nanostruc-
tured lipid carrier. NLCs were prepared by solvent diffusion
method at 70 C which exhibit high entrapment efﬁciency with
sustained release of drug up to the period of 36 h. DSC and
XRD conﬁrm the transformation of crystal nature of drug into
amorphous nature that plays an important role in enhance-
ment of absorption rate followed by bioavailability. Particle
size and TEM study conﬁrms nano sized discrete spherical
globules with smooth surface area. Stability study of optimized
formulation at room condition shows extremely stable formu-
lation for the period of six months that support the fact that
dried lyophilized nanocarriers may remain stable for longer
period of time.
Result of pharmacokinetic study shows pronounced
improvement in pharmacokinetic parameters (Cmax, Tmax
and [AUC]0–24) which are responsible for enhanced absorption
and bioavailability of drug from NLCs. The pharmacokinetic
study of RLX loaded NLCs showed 3.75-fold signiﬁcant
improvement in bioavailability of poorly soluble RLX than
plain drug suspension which bestows its potential role as suit-
able carrier system for oral delivery of RLX in the treatment of
osteoporosis. For the commercial purpose, this dried NLCs
product can be used orally either by incorporating into capsule
or by making dispersion of powder in distilled water.
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